• LAST PRICE
    1.1700
  • TODAY'S CHANGE (%)
    Trending Down-0.0200 (-1.6807%)
  • Bid / Lots
    1.1600/ 10
  • Ask / Lots
    1.1800/ 1
  • Open / Previous Close
    1.1700 / 1.1900
  • Day Range
    Low 1.1400
    High 1.1801
  • 52 Week Range
    Low 0.4986
    High 1.7200
  • Volume
    389,122
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 1.19
TimeVolumeSLS
09:32 ET215221.1801
09:33 ET66901.16
09:35 ET25421.15
09:37 ET15001.165
09:39 ET23001.165
09:42 ET6001.175
09:44 ET5441.165
09:46 ET61151.16
09:48 ET31001.16
09:50 ET180631.145
09:51 ET12991.145
09:53 ET33191.1484
09:55 ET8881.1473
09:57 ET4991.1594
10:00 ET15071.1504
10:02 ET28001.16
10:04 ET5001.155
10:06 ET32501.1599
10:09 ET2001.155
10:13 ET6001.155
10:15 ET12001.1585
10:18 ET105001.155
10:20 ET2001.155
10:22 ET1001.155
10:24 ET115631.15
10:26 ET63411.15
10:27 ET4001.15
10:29 ET2001.15
10:31 ET12991.15
10:33 ET1001.15
10:36 ET36001.1536
10:38 ET22001.15
10:40 ET8181.155
10:44 ET1001.15
10:45 ET12001.155
10:47 ET2501.1591
10:51 ET23681.1599
10:54 ET3001.155
10:56 ET5001.15
10:58 ET112521.145
11:00 ET9501.1499
11:02 ET158681.145
11:12 ET1681.15
11:14 ET2501.15
11:16 ET6001.155
11:18 ET61101.155
11:20 ET8001.155
11:21 ET4001.155
11:23 ET27001.155
11:25 ET13001.155
11:32 ET50621.155
11:34 ET2631.155
11:36 ET2001.155
11:38 ET2001.155
11:39 ET10001.15
11:41 ET5001.155
11:45 ET3001.1509
11:50 ET2501.16
11:52 ET6001.1598
12:01 ET280991.165
12:03 ET121251.165
12:06 ET43281.155
12:12 ET6001.1501
12:19 ET42841.155
12:24 ET12491.155
12:28 ET7001.1506
12:30 ET1001.155
12:42 ET23231.155
12:44 ET1001.155
12:46 ET9481.1508
12:50 ET31031.155
12:51 ET29001.165
12:55 ET21001.165
12:57 ET9001.1609
01:00 ET30251.16
01:04 ET152851.155
01:09 ET1991.15
01:11 ET31501.1599
01:24 ET4081.16
01:27 ET92511.165
01:31 ET30001.16
01:33 ET5001.165
01:38 ET2001.17
01:44 ET9001.17
01:45 ET10001.1692
01:49 ET36001.1699
01:56 ET10001.1692
02:03 ET3001.165
02:09 ET1001.165
02:12 ET1111.165
02:14 ET1001.165
02:18 ET2221.165
02:21 ET1111.165
02:23 ET116891.17
02:25 ET1001.175
02:27 ET48001.175
02:32 ET37001.18
02:34 ET23001.175
02:36 ET1001.18
02:38 ET82411.17
02:39 ET14001.17
02:41 ET150021.175
02:45 ET33001.17
02:48 ET2991.18
02:50 ET77001.165
02:52 ET25001.165
02:54 ET17121.164719
02:59 ET1001.165
03:03 ET3001.165
03:08 ET15001.1653
03:10 ET2001.165
03:21 ET1501.1613
03:24 ET1501.16
03:26 ET32031.1695
03:28 ET105731.17
03:30 ET4001.17
03:32 ET5001.165
03:35 ET1841.165
03:39 ET2501.165
03:46 ET10001.1699
03:48 ET2001.17
03:50 ET18581.1695
03:51 ET2001.1605
03:53 ET1781.17
03:55 ET15001.165
03:57 ET32501.165
04:00 ET35751.17
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesSLS
Sellas Life Sciences Group Inc
76.6M
-1.3x
---
United StatesALXO
ALX Oncology Holdings Inc
76.4M
-0.4x
---
United StatesMNPR
Monopar Therapeutics Inc
77.2M
-7.3x
---
United StatesRAPT
RAPT Therapeutics Inc
77.8M
-0.7x
---
United StatesIOBT
IO Biotech Inc
79.1M
-0.8x
---
United StatesAVTE
Aerovate Therapeutics Inc
80.5M
-0.9x
---
As of 2024-11-04

Company Information

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of novel therapeutics for a range of cancer indications. The Company's product candidates, galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9), inhibitor. GPS is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed from GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of Greater China.

Contact Information

Headquarters
7 TIMES SQUARE, SUITE 2503NEW YORK, NY, United States 10036
Phone
646-200-5278
Fax
302-636-5454

Executives

Independent Chairman of the Board
Jane Wasman
President, Chief Executive Officer, Director
Angelos Stergiou
Chief Financial Officer
John Burns
Senior Vice President - Clinical Development
Dragan Cicic
Vice President - Head of Regulatory Affairs, Chemistry, Manufacturing, and Controls (CMC) and Quality
Andrew Elnatan

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$76.6M
Revenue (TTM)
$0.00
Shares Outstanding
64.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
2.44
EPS
$-0.93
Book Value
$-0.25
P/E Ratio
-1.3x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.